“Ironwood’s mid- to late-stage pipeline is advancing, with a string of recent successes, and we expect multiple near-term, value-creating catalysts from our clinical development programs. In addition, we are commercializing two products in the U.S., with a new drug application for a third product currently under FDA review,” said Dr. Currie. “At this exciting and transformational time for Ironwood, Chris’s collaborative leadership style, dedication to patients and track record of translating science into important therapies for patients will help Ironwood scale our capabilities and enhance the speed, quality, functional integration and innovative means by which we advance our medicines to patients.”
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at firstname.lastname@example.org